Andrew M. Brunner
YOU?
Author Swipe
View article: ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features
ETNK1 mutations define a distinct subset of myeloid neoplasms with unique cytogenetic and molecular features Open
Background: Mutations in ethanolamine kinase-1 (ETNK1) have been identified in a wide range of myeloid neoplasms (MN), but their clinical significance remains poorly defined. Key gaps remain, including the true prevalence, variant- and dis…
View article: BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study
BMS-986397, a first-in-class casein kinase 1α (CK1α) degrader in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): A phase 1 dose escalation study Open
Introduction: Patients with relapsed or refractory (R/R) AML or high-risk MDS (HR-MDS) have limited therapeutic options and poor outcomes. BMS-986397 (CC-91633) repurposes the CRL4CRBN E3 ubiquitin ligase to target Casein kinase 1α (CK1α) …
View article: Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes
Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes Open
Introduction: In November 2021 ropeginterferon alpha-2B (ropeg) was approved by the FDA for front-line management of PV regardless of thrombotic risk based on the LOW-PV and PROUD/CONTINUATION-PV trials that demonstrated high rates of hema…
View article: Malignant Melanoma: The Relationship Between Sunscreen Use and Cancer Risk – A Systematic Review and Meta-analysis
Malignant Melanoma: The Relationship Between Sunscreen Use and Cancer Risk – A Systematic Review and Meta-analysis Open
No association was found between melanoma risk and sunscreen use. Many of the studies showed methodological inaccuracies and further studies examining sunscreen application frequency and behavior towards sun exposure in more detail are nee…
View article: Clinical Utility of Plasma Microbial Cell-Free DNA Surveillance in Neutropenic Patients with Acute Myeloid Leukemia Undergoing Outpatient Chemotherapy: A Case Series
Clinical Utility of Plasma Microbial Cell-Free DNA Surveillance in Neutropenic Patients with Acute Myeloid Leukemia Undergoing Outpatient Chemotherapy: A Case Series Open
Background/Objectives: The main objective of the study is to assess the clinical utility of microbial cell-free DNA (mcfDNA) in neutropenic patients diagnosed with acute myeloid leukemia (AML) undergoing chemotherapy in the outpatient sett…
View article: Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis
Sialylated CD43 is a glyco-immune checkpoint for macrophage phagocytosis Open
Macrophages in the tumor microenvironment exert potent anti-tumorigenic activity through phagocytosis. Yet therapeutics that enhance macrophage phagocytosis have not improved outcomes in clinical trials for patients with acute myeloid leuk…
View article: Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms Open
Context.— Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.— To propose a standardized approach to MDS evaluation in…
View article: NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025 Open
The NCCN Guidelines for Myelodysplastic Syndromes (MDS) provide recommendations for the evaluation, diagnosis, and comprehensive care of patients with MDS based on a review of recent clinical evidence that has led to important advances in …
View article: Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes
Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes Open
Background: Lower-risk myelodysplastic syndromes (LR-MDS) are characterized by progressive cytopenias related to malignant clonal expansion. MDS progenitors exert clonal dominance but ineffective hematopoiesis; MDS progenitors may rely on …
View article: Supplemental Figure 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Supplemental Figure 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Open
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
View article: Data from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Data from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Open
Purpose: IDH1 (isocitrate dehydrogenase 1) mutations occur in 5-10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use in patients with IDH1-mutated AML. Patients and Methods: We conducted a mu…
View article: Supplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Supplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Open
Marrow IDH1 VAF prior to Transplant and Maintenance
View article: Supplemental Figure 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Supplemental Figure 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Open
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
View article: Supplemental Figure 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Supplemental Figure 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Open
Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.
View article: Supplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Supplemental Table 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Open
Marrow IDH1 VAF prior to Transplant and Maintenance
View article: Supplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Supplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Open
Representativeness of Study Participants
View article: Supplemental Figure 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Supplemental Figure 2 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Open
Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status
View article: Supplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
Supplemental Table 1 from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia Open
Representativeness of Study Participants
View article: Risk prediction for clonal cytopenia: multicenter real-world evidence
Risk prediction for clonal cytopenia: multicenter real-world evidence Open
Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without a m…
View article: Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) Open
Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS therapies holds the prom…
View article: Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia
Racial and ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia Open
Background Clinical trial participation at Comprehensive Cancer Centers (CCC) is inequitable for minoritized racial and ethnic groups with acute leukemia. CCCs care for a high proportion of adults with acute leukemia. It is unclear if part…
View article: Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms
Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms Open
Background: GSK3326595 is a potent, selective, reversible protein arginine methyltransferase 5 (PRMT5) inhibitor under investigation for treatment of myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid…
View article: In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and heart failure: Insights from the National Readmissions Database
In-Hospital and readmission outcomes of patients with myeloproliferative neoplasms and heart failure: Insights from the National Readmissions Database Open
Among patients hospitalized for HF, MPN was associated with increased risk of in-hospital death, and 90-day CV-related readmissions (driven primarily by thrombotic readmissions). Further investigation is needed in order to improve outcomes…
View article: Phase Ib study of sabatolimab (<scp>MBG453</scp>), a novel immunotherapy targeting <scp>TIM‐3</scp> antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes
Phase Ib study of sabatolimab (<span>MBG453</span>), a novel immunotherapy targeting <span>TIM‐3</span> antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes Open
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised Internationa…
View article: Are We Ready For “Triplet” Therapy in Higher-Risk MDS?
Are We Ready For “Triplet” Therapy in Higher-Risk MDS? Open
Higher-risk Myelodysplastic Syndromes/Neoplasms (MDS) represent an ongoing therapeutic challenge, with few effective therapies, many of which may have limited use in this older patient population often with considerations around comorbidit…
View article: Methods of Estimating Renal Function for Use in Clinical Trial Eligibility Criteria Widely Vary in Phase II and III Clinical Trials in Acute Myeloid Leukemia
Methods of Estimating Renal Function for Use in Clinical Trial Eligibility Criteria Widely Vary in Phase II and III Clinical Trials in Acute Myeloid Leukemia Open
Background Renal function is an important parameter to inform drug-dosing in oncology. In acute myeloid leukemia (AML), commonly used therapies or their metabolites are renally cleared. Several equations are commonly used to estimate renal…